IMforte regimen: The first and only FDA-approved combination for maintenance treatment in 1L ES-SCLC
Meeting Host
GenentechDescription
Program Overview
- An overview of the SCLC landscape
- An introduction to the IMforte clinical trial design, patient characteristics, and pivotal efficacy and safety data
When
December 2, 2025
Where
Virtual
Please register via attached invite (below)
Time
6:00 - 7:00 p.m.
Target Audience
MDs, PAs, NPs, RNs, Residents, Fellows, and PharmDs
Speaker
Mark Socinski, MD
Executive Medical Director
AdventHealth Cancer Institute
Meeting Flyer, Agenda & Registration
See meeting details in the flyer linked below.
